WO1998037078A1 - CHIMIE EN PHASE SOLIDE ET SYNTHESE COMBINATOIRE DE THIOPHENES SUBSTITUES ET DE SERIES DE CES thiofènes SUBSTITUES - Google Patents
CHIMIE EN PHASE SOLIDE ET SYNTHESE COMBINATOIRE DE THIOPHENES SUBSTITUES ET DE SERIES DE CES thiofènes SUBSTITUES Download PDFInfo
- Publication number
- WO1998037078A1 WO1998037078A1 PCT/DK1998/000035 DK9800035W WO9837078A1 WO 1998037078 A1 WO1998037078 A1 WO 1998037078A1 DK 9800035 W DK9800035 W DK 9800035W WO 9837078 A1 WO9837078 A1 WO 9837078A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- alkyl
- substrate
- halogen
- aryl
- Prior art date
Links
- 229930192474 thiophene Natural products 0.000 title claims abstract description 54
- 150000003577 thiophenes Chemical class 0.000 title abstract description 45
- 238000003786 synthesis reaction Methods 0.000 title abstract description 26
- 230000015572 biosynthetic process Effects 0.000 title abstract description 21
- 238000003491 array Methods 0.000 title description 17
- 239000007790 solid phase Substances 0.000 title description 4
- 239000000758 substrate Substances 0.000 claims abstract description 79
- 150000001875 compounds Chemical class 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 46
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims abstract description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000006243 chemical reaction Methods 0.000 claims abstract description 25
- 239000000543 intermediate Substances 0.000 claims abstract description 16
- 238000012216 screening Methods 0.000 claims abstract description 16
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims abstract description 13
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000007960 acetonitrile Chemical class 0.000 claims abstract description 8
- 230000029936 alkylation Effects 0.000 claims abstract description 6
- 238000005804 alkylation reaction Methods 0.000 claims abstract description 6
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 79
- 125000003118 aryl group Chemical group 0.000 claims description 66
- 229910052736 halogen Chemical group 0.000 claims description 55
- 150000002367 halogens Chemical group 0.000 claims description 54
- -1 cyano, hydroxy Chemical group 0.000 claims description 51
- 125000003545 alkoxy group Chemical group 0.000 claims description 50
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 49
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 48
- 125000004104 aryloxy group Chemical group 0.000 claims description 37
- 125000004986 diarylamino group Chemical group 0.000 claims description 37
- 125000001072 heteroaryl group Chemical group 0.000 claims description 35
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 25
- 125000005647 linker group Chemical group 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 20
- 150000002431 hydrogen Chemical group 0.000 claims description 18
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 17
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 10
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 230000007017 scission Effects 0.000 claims description 8
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 6
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 238000006073 displacement reaction Methods 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 230000000269 nucleophilic effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005977 Ethylene Substances 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000005110 aryl thio group Chemical group 0.000 claims description 3
- 238000010511 deprotection reaction Methods 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 5
- 239000012039 electrophile Substances 0.000 claims 3
- 230000002152 alkylating effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract description 17
- 229920005989 resin Polymers 0.000 abstract description 16
- 239000011347 resin Substances 0.000 abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 6
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- DKGYESBFCGKOJC-UHFFFAOYSA-N thiophen-3-amine Chemical class NC=1C=CSC=1 DKGYESBFCGKOJC-UHFFFAOYSA-N 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 2
- 150000003141 primary amines Chemical class 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 125000001424 substituent group Chemical group 0.000 abstract description 2
- 230000006181 N-acylation Effects 0.000 abstract 1
- 150000001350 alkyl halides Chemical class 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
- 238000000844 transformation Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 11
- 150000004985 diamines Chemical class 0.000 description 11
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 7
- 239000004793 Polystyrene Substances 0.000 description 7
- 229920002223 polystyrene Polymers 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 150000002390 heteroarenes Chemical class 0.000 description 6
- 150000002894 organic compounds Chemical class 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 230000031018 biological processes and functions Effects 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 229940074993 carbon disulfide Drugs 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 125000002541 furyl group Chemical class 0.000 description 3
- 125000005283 haloketone group Chemical group 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 229920005990 polystyrene resin Polymers 0.000 description 3
- 125000004076 pyridyl group Chemical class 0.000 description 3
- 125000000168 pyrrolyl group Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 0 *c1c(*)[s]c(N(*)*)c1* Chemical compound *c1c(*)[s]c(N(*)*)c1* 0.000 description 2
- DDHUNHGZUHZNKB-UHFFFAOYSA-N 2,2-dimethylpropane-1,3-diamine Chemical compound NCC(C)(C)CN DDHUNHGZUHZNKB-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000005700 Putrescine Substances 0.000 description 2
- 239000003875 Wang resin Substances 0.000 description 2
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 2
- WTSXICLFTPPDTL-UHFFFAOYSA-N pentane-1,3-diamine Chemical compound CCC(N)CCN WTSXICLFTPPDTL-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 150000003458 sulfonic acid derivatives Chemical class 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SHPIBZXFYWMQBR-UHFFFAOYSA-M (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-hydroxy-2-phenyl-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CS1 SHPIBZXFYWMQBR-UHFFFAOYSA-M 0.000 description 1
- RMTDKXQYAKLQKF-INIZCTEOSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-sulfanylpropanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CS)C(=O)O)C3=CC=CC=C3C2=C1 RMTDKXQYAKLQKF-INIZCTEOSA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 description 1
- JZTKZVJMSCONAK-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-hydroxypropanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CO)C(O)=O)C3=CC=CC=C3C2=C1 JZTKZVJMSCONAK-INIZCTEOSA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 1
- VCFCFPNRQDANPN-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCC)C(O)=O)C3=CC=CC=C3C2=C1 VCFCFPNRQDANPN-IBGZPJMESA-N 0.000 description 1
- JBIJSEUVWWLFGV-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC)C(O)=O)C3=CC=CC=C3C2=C1 JBIJSEUVWWLFGV-SFHVURJKSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- IZKGGDFLLNVXNZ-KRWDZBQOSA-N (2s)-5-amino-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)N)C(O)=O)C3=CC=CC=C3C2=C1 IZKGGDFLLNVXNZ-KRWDZBQOSA-N 0.000 description 1
- JGUYYODGVQXZAY-SFTDATJTSA-N (3s,4s)-4-(9h-fluoren-9-ylmethoxycarbonylamino)-3-hydroxy-6-methylheptanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)[C@@H](O)CC(O)=O)C3=CC=CC=C3C2=C1 JGUYYODGVQXZAY-SFTDATJTSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- FMZXNVLFJHCSAF-DNVCBOLYSA-N (6R,7R)-3-[(4-carbamoyl-1-pyridin-1-iumyl)methyl]-8-oxo-7-[(1-oxo-2-thiophen-2-ylethyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC=3SC=CC=3)[C@H]2SC1 FMZXNVLFJHCSAF-DNVCBOLYSA-N 0.000 description 1
- YWWSWEIXJXYQJB-AATRIKPKSA-N (e)-n,n'-diethylbut-2-ene-1,4-diamine Chemical compound CCNC\C=C\CNCC YWWSWEIXJXYQJB-AATRIKPKSA-N 0.000 description 1
- QXDVFQAKOKIPCM-ONEGZZNKSA-N (e)-n,n'-dimethylbut-2-ene-1,4-diamine Chemical compound CNC\C=C\CNC QXDVFQAKOKIPCM-ONEGZZNKSA-N 0.000 description 1
- FOTRKCAZUSJCQD-UHFFFAOYSA-N (methylsulfonyl)acetonitrile Chemical compound CS(=O)(=O)CC#N FOTRKCAZUSJCQD-UHFFFAOYSA-N 0.000 description 1
- UYBWIEGTWASWSR-UHFFFAOYSA-N 1,3-diaminopropan-2-ol Chemical compound NCC(O)CN UYBWIEGTWASWSR-UHFFFAOYSA-N 0.000 description 1
- SJLSQITZGUTOMN-UHFFFAOYSA-N 1,4-diazepan-6-ol Chemical compound OC1CNCCNC1 SJLSQITZGUTOMN-UHFFFAOYSA-N 0.000 description 1
- PUVGNCCFZPFTIE-UHFFFAOYSA-N 1,4-diazepan-6-yl acetate Chemical compound CC(=O)OC1CNCCNC1 PUVGNCCFZPFTIE-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- NVEPPWDVLBMNMB-SNAWJCMRSA-N 1-methyl-2-[(e)-2-(3-methylthiophen-2-yl)ethenyl]-5,6-dihydro-4h-pyrimidine Chemical compound CN1CCCN=C1\C=C\C1=C(C)C=CS1 NVEPPWDVLBMNMB-SNAWJCMRSA-N 0.000 description 1
- NSMWYRLQHIXVAP-UHFFFAOYSA-N 2,5-dimethylpiperazine Chemical compound CC1CNC(C)CN1 NSMWYRLQHIXVAP-UHFFFAOYSA-N 0.000 description 1
- IFNWESYYDINUHV-UHFFFAOYSA-N 2,6-dimethylpiperazine Chemical compound CC1CNCC(C)N1 IFNWESYYDINUHV-UHFFFAOYSA-N 0.000 description 1
- VWGJUXTWIWCQGL-UHFFFAOYSA-M 2-(2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetyl)oxyethyl-diethyl-methylazanium;bromide Chemical compound [Br-].C=1C=CSC=1C(O)(C(=O)OCC[N+](C)(CC)CC)C1CCCC1 VWGJUXTWIWCQGL-UHFFFAOYSA-M 0.000 description 1
- MGHMWKZOLAAOTD-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NC(C(=O)O)CC1=CNC2=CC=CC=C12 MGHMWKZOLAAOTD-UHFFFAOYSA-N 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- QKHWUKPTSMULMZ-UHFFFAOYSA-N 2-(aminomethyl)-3,3,5-trimethylcyclopentan-1-amine Chemical compound CC1CC(C)(C)C(CN)C1N QKHWUKPTSMULMZ-UHFFFAOYSA-N 0.000 description 1
- UPMGJEMWPQOACJ-UHFFFAOYSA-N 2-[4-[(2,4-dimethoxyphenyl)-(9h-fluoren-9-ylmethoxycarbonylamino)methyl]phenoxy]acetic acid Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(O)=O)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPMGJEMWPQOACJ-UHFFFAOYSA-N 0.000 description 1
- ZHKQIADIIYMFOZ-UHFFFAOYSA-N 2-[9h-fluoren-9-ylmethoxycarbonyl(methyl)amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)N(CC(O)=O)C)C3=CC=CC=C3C2=C1 ZHKQIADIIYMFOZ-UHFFFAOYSA-N 0.000 description 1
- KGHGZRVXCKCJGX-UHFFFAOYSA-N 2-bromo-1-(4-phenylphenyl)ethanone Chemical compound C1=CC(C(=O)CBr)=CC=C1C1=CC=CC=C1 KGHGZRVXCKCJGX-UHFFFAOYSA-N 0.000 description 1
- YHXHHGDUANVQHE-UHFFFAOYSA-N 2-bromo-1-naphthalen-2-ylethanone Chemical compound C1=CC=CC2=CC(C(=O)CBr)=CC=C21 YHXHHGDUANVQHE-UHFFFAOYSA-N 0.000 description 1
- VYWPPRLJNVHPEU-UHFFFAOYSA-N 2-chloro-1-(2,4-dichlorophenyl)ethanone Chemical compound ClCC(=O)C1=CC=C(Cl)C=C1Cl VYWPPRLJNVHPEU-UHFFFAOYSA-N 0.000 description 1
- XEUXCKGGBTVKCX-UHFFFAOYSA-N 2-chloro-1-(4-chloro-3-methylphenyl)ethanone Chemical compound CC1=CC(C(=O)CCl)=CC=C1Cl XEUXCKGGBTVKCX-UHFFFAOYSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 1
- UJUAARGDLUVXPB-UHFFFAOYSA-N 2-piperazin-1-yl-n-(pyridin-3-ylmethyl)ethanamine Chemical compound C=1C=CN=CC=1CNCCN1CCNCC1 UJUAARGDLUVXPB-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- PCNAYTOJVHTNKK-UHFFFAOYSA-N 2-sulfonylacetonitrile Chemical compound O=S(=O)=CC#N PCNAYTOJVHTNKK-UHFFFAOYSA-N 0.000 description 1
- RNLHGQLZWXBQNY-UHFFFAOYSA-N 3-(aminomethyl)-3,5,5-trimethylcyclohexan-1-amine Chemical compound CC1(C)CC(N)CC(C)(CN)C1 RNLHGQLZWXBQNY-UHFFFAOYSA-N 0.000 description 1
- ZLWLKVQCHZSSEL-UHFFFAOYSA-N 4,5-dibromo-n-(4-bromophenyl)thiophene-2-carboxamide Chemical compound S1C(Br)=C(Br)C=C1C(=O)NC1=CC=C(Br)C=C1 ZLWLKVQCHZSSEL-UHFFFAOYSA-N 0.000 description 1
- IVOPPVFDOTYTLF-UHFFFAOYSA-N 4-amino-2-(2-aminoethylamino)-5-benzoylthiophene-3-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N#CC1=C(NCCN)SC(C(=O)C=2C=CC=CC=2)=C1N IVOPPVFDOTYTLF-UHFFFAOYSA-N 0.000 description 1
- HVCYXOVITCKDCK-UHFFFAOYSA-N 4-piperidin-3-ylbutan-1-amine Chemical compound NCCCCC1CCCNC1 HVCYXOVITCKDCK-UHFFFAOYSA-N 0.000 description 1
- PRNRUOJLUPUJDN-UHFFFAOYSA-N 4-piperidin-4-ylpiperidine Chemical compound C1CNCCC1C1CCNCC1 PRNRUOJLUPUJDN-UHFFFAOYSA-N 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 108010063919 Glucagon Receptors Proteins 0.000 description 1
- 102100040890 Glucagon receptor Human genes 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- LDYJXVUOVPVZKA-UHFFFAOYSA-N Methaphenilene Chemical compound C=1C=CC=CC=1N(CCN(C)C)CC1=CC=CS1 LDYJXVUOVPVZKA-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- CJKRXEBLWJVYJD-UHFFFAOYSA-N N,N'-diethylethylenediamine Chemical compound CCNCCNCC CJKRXEBLWJVYJD-UHFFFAOYSA-N 0.000 description 1
- AOQVETXWSCPNPY-UHFFFAOYSA-N NCCCCNc([s]c(C(c1ccccc1)=O)c1N)c1S(c(cc1)ccc1Cl)(=O)=O Chemical compound NCCCCNc([s]c(C(c1ccccc1)=O)c1N)c1S(c(cc1)ccc1Cl)(=O)=O AOQVETXWSCPNPY-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- RCGYDFVCAAKKNG-UHFFFAOYSA-N Thenyldiamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC=1C=CSC=1 RCGYDFVCAAKKNG-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JGKRSFYTHYYJNX-ONNFQVAWSA-N [(e)-(5-cyanothiophen-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=CC=C(C#N)S1 JGKRSFYTHYYJNX-ONNFQVAWSA-N 0.000 description 1
- GKXVJHDEWHKBFH-UHFFFAOYSA-N [2-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=CC=C1CN GKXVJHDEWHKBFH-UHFFFAOYSA-N 0.000 description 1
- IOPDKAMORVTMHE-UHFFFAOYSA-N [2-[hydroxymethyl(propyl)amino]ethylamino]methanol Chemical compound CCCN(CO)CCNCO IOPDKAMORVTMHE-UHFFFAOYSA-N 0.000 description 1
- QLBRROYTTDFLDX-UHFFFAOYSA-N [3-(aminomethyl)cyclohexyl]methanamine Chemical compound NCC1CCCC(CN)C1 QLBRROYTTDFLDX-UHFFFAOYSA-N 0.000 description 1
- FDLQZKYLHJJBHD-UHFFFAOYSA-N [3-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(CN)=C1 FDLQZKYLHJJBHD-UHFFFAOYSA-N 0.000 description 1
- OXIKYYJDTWKERT-UHFFFAOYSA-N [4-(aminomethyl)cyclohexyl]methanamine Chemical compound NCC1CCC(CN)CC1 OXIKYYJDTWKERT-UHFFFAOYSA-N 0.000 description 1
- ISKQADXMHQSTHK-UHFFFAOYSA-N [4-(aminomethyl)phenyl]methanamine Chemical compound NCC1=CC=C(CN)C=C1 ISKQADXMHQSTHK-UHFFFAOYSA-N 0.000 description 1
- KDBBCFRGLKZRQJ-UHFFFAOYSA-M [4-[hydroxy(dithiophen-2-yl)methyl]cyclohexyl]-trimethylazanium;bromide Chemical compound [Br-].C1CC([N+](C)(C)C)CCC1C(O)(C=1SC=CC=1)C1=CC=CS1 KDBBCFRGLKZRQJ-UHFFFAOYSA-M 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229950005258 cefalonium Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- XAEXSWVTEJHRMH-UHFFFAOYSA-N chloropyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=C(Cl)S1 XAEXSWVTEJHRMH-UHFFFAOYSA-N 0.000 description 1
- 229950005434 chloropyrilene Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229950004773 citenazone Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- GEQHKFFSPGPGLN-UHFFFAOYSA-N cyclohexane-1,3-diamine Chemical compound NC1CCCC(N)C1 GEQHKFFSPGPGLN-UHFFFAOYSA-N 0.000 description 1
- VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 description 1
- QTBFZNSOXHKZOD-UHFFFAOYSA-M diethyl-[2-(2-hydroxy-2-phenyl-2-thiophen-2-ylacetyl)oxyethyl]-methylazanium;bromide Chemical compound [Br-].C=1C=CC=CC=1C(O)(C(=O)OCC[N+](C)(CC)CC)C1=CC=CS1 QTBFZNSOXHKZOD-UHFFFAOYSA-M 0.000 description 1
- CBYWMRHUUVRIAF-UHFFFAOYSA-N diethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(CC)CC)C1=CC=CS1 CBYWMRHUUVRIAF-UHFFFAOYSA-N 0.000 description 1
- 229950009987 diethylthiambutene Drugs 0.000 description 1
- KYCIUIVANPKXLW-UHFFFAOYSA-N dimethyl-(2-phenoxyethyl)-(thiophen-2-ylmethyl)azanium Chemical compound C=1C=CSC=1C[N+](C)(C)CCOC1=CC=CC=C1 KYCIUIVANPKXLW-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- HOKNTYWEKQQKGV-UHFFFAOYSA-N disulfonylmethane Chemical class O=S(=O)=C=S(=O)=O HOKNTYWEKQQKGV-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229950005494 heteronium bromide Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229950000498 methaphenilene Drugs 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- 229940073584 methylene chloride Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005121 morantel Drugs 0.000 description 1
- GDJIVWPKHAWKIO-UHFFFAOYSA-N n,n',2-trimethylpropane-1,3-diamine Chemical compound CNCC(C)CNC GDJIVWPKHAWKIO-UHFFFAOYSA-N 0.000 description 1
- MFIGJRRHGZYPDD-UHFFFAOYSA-N n,n'-di(propan-2-yl)ethane-1,2-diamine Chemical compound CC(C)NCCNC(C)C MFIGJRRHGZYPDD-UHFFFAOYSA-N 0.000 description 1
- DHLUQZDOGQUIOO-UHFFFAOYSA-N n,n'-diethylbut-2-yne-1,4-diamine Chemical compound CCNCC#CCNCC DHLUQZDOGQUIOO-UHFFFAOYSA-N 0.000 description 1
- WHDUKLPCKZTPFY-UHFFFAOYSA-N n,n'-diethylbutane-1,4-diamine Chemical compound CCNCCCCNCC WHDUKLPCKZTPFY-UHFFFAOYSA-N 0.000 description 1
- BEPGHZIEOVULBU-UHFFFAOYSA-N n,n'-diethylpropane-1,3-diamine Chemical compound CCNCCCNCC BEPGHZIEOVULBU-UHFFFAOYSA-N 0.000 description 1
- VCUPOEDTGSOKCM-UHFFFAOYSA-N n,n'-dihexylethane-1,2-diamine Chemical compound CCCCCCNCCNCCCCCC VCUPOEDTGSOKCM-UHFFFAOYSA-N 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- OHTVZIMDFZDLPB-UHFFFAOYSA-N n,n'-dipropylbutane-1,4-diamine Chemical compound CCCNCCCCNCCC OHTVZIMDFZDLPB-UHFFFAOYSA-N 0.000 description 1
- VATUKUMHBXZSCD-UHFFFAOYSA-N n,n'-dipropylethane-1,2-diamine Chemical compound CCCNCCNCCC VATUKUMHBXZSCD-UHFFFAOYSA-N 0.000 description 1
- UQUPIHHYKUEXQD-UHFFFAOYSA-N n,n′-dimethyl-1,3-propanediamine Chemical compound CNCCCNC UQUPIHHYKUEXQD-UHFFFAOYSA-N 0.000 description 1
- DRQKKEYKSSAVTO-UHFFFAOYSA-N n-[4-(2-chloroacetyl)phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=C(C(=O)CCl)C=C1 DRQKKEYKSSAVTO-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical class 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229950006841 oxitefonium bromide Drugs 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229960003293 penthienate Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- LTEKQAPRXFBRNN-UHFFFAOYSA-N piperidin-4-ylmethanamine Chemical compound NCC1CCNCC1 LTEKQAPRXFBRNN-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- YSAUAVHXTIETRK-AATRIKPKSA-N pyrantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1 YSAUAVHXTIETRK-AATRIKPKSA-N 0.000 description 1
- 229960005134 pyrantel Drugs 0.000 description 1
- 125000003226 pyrazolyl group Chemical class 0.000 description 1
- 125000002098 pyridazinyl group Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- ZLOXYEZYWCTXHU-UHFFFAOYSA-N tenonitrozole Chemical compound S1C([N+](=O)[O-])=CN=C1NC(=O)C1=CC=CS1 ZLOXYEZYWCTXHU-UHFFFAOYSA-N 0.000 description 1
- 229960004480 tenonitrozole Drugs 0.000 description 1
- 125000003831 tetrazolyl group Chemical class 0.000 description 1
- KLOHYVOVXOUKQI-UHFFFAOYSA-N thenalidine Chemical compound C1CN(C)CCC1N(C=1C=CC=CC=1)CC1=CC=CS1 KLOHYVOVXOUKQI-UHFFFAOYSA-N 0.000 description 1
- 229960002304 thenalidine Drugs 0.000 description 1
- 229960004283 thenyldiamine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical class 0.000 description 1
- 229950009591 thihexinol methylbromide Drugs 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- GLQWRXYOTXRDNH-UHFFFAOYSA-N thiophen-2-amine Chemical class NC1=CC=CS1 GLQWRXYOTXRDNH-UHFFFAOYSA-N 0.000 description 1
- CUPOOAWTRIURFT-UHFFFAOYSA-N thiophene-2-carbonitrile Chemical compound N#CC1=CC=CS1 CUPOOAWTRIURFT-UHFFFAOYSA-N 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229950008807 tibrofan Drugs 0.000 description 1
- PFENFDGYVLAFBR-UHFFFAOYSA-N tinoridine Chemical compound C1CC=2C(C(=O)OCC)=C(N)SC=2CN1CC1=CC=CC=C1 PFENFDGYVLAFBR-UHFFFAOYSA-N 0.000 description 1
- 229950010298 tinoridine Drugs 0.000 description 1
- JWIXXNLOKOAAQT-UHFFFAOYSA-N tipepidine Chemical compound C1N(C)CCCC1=C(C=1SC=CC=1)C1=CC=CS1 JWIXXNLOKOAAQT-UHFFFAOYSA-N 0.000 description 1
- 229960000896 tipepidine Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
Definitions
- the present invention relates to the field of solid phase chemistry. More specifically, the invention provides a method for solid phase and combinatorial synthesis of organic compounds, and most particularly, a therapeutically important class of compounds, namely diversely substituted thiophenes.
- the synthetic sequence disclosed in this invention is a variant of related thiophene syntheses (ref. 11-16), adapted and optimized for its realization on a solid support.
- Linker a molecule with at least two reactive sites, which permit its covalent attachment to other molecules or to a substrate. Either the bond of the linker to the substrate or the bond of the linker to other molecules attached to it or the linker itself must be cleavable upon selective exposure to an activator such as a selected chemical activator or other specific conditions, e.g. by treatment with a strong acid or by exposure to electromagnetic radiation or by metal catalysis.
- an activator such as a selected chemical activator or other specific conditions, e.g. by treatment with a strong acid or by exposure to electromagnetic radiation or by metal catalysis.
- Protecting group A material which is chemically bound to a molecule or a substrate and which may be removed upon selective exposure to an activator such as a selected chemical activator or other specific conditions, e.g. by treatment with a strong acid or by exposure to electromagnetic radiation or by metal catalysis.
- Combinatorial synthesis an ordered strategy for parallel synthesis of arrays of single compounds or mixtures, by sequential addition of reagents.
- Receptor A material that has an affinity for a given ligand.
- Receptors may be naturally- occurring or synthetic molecules or aggregates of molecules. Also, they can be employed in their unaltered state or as aggregates with other species. Receptors may be attached, covalently or non-covalently, to a binding material or a substrate, either directly or via a linking substance.
- the invention provides a rapid approach for combinatorial synthesis and screening of arrays of thiophene derivatives as a therapeutically important class of compounds. It provides a solid phase synthesis of these derivatives, which eliminates purification and isolation steps and thus highly increases synthesis efficiency.
- This patent disclosure also describes an important extension of solid phase synthesis methods to nonoligomeric organic compounds.
- the application of the present invention is the rapid preparation and screening, preferably in parallel and simultaneous fashion, of a large number of differently substituted thiophenes of the general formula I
- A is a electron-withdrawing group of formula
- Y is an amino group or an aryl group, such as phenyl
- E is a group of formula
- R is alkylene optionally substituted with hydrogen, alkyl, aryl, heteroaryl, alkoxy, aryloxy, cyano, hydroxy, dialkylamino, arylalkylamino, diarylamino or halogen, such as methylene, 1 ,2-ethylene, 1 ,4-butylene, or 1 ,3-pentylene,
- R is hydrogen, alkyl optionally substituted with hydroxy, halogen, cyano, alkoxy, aryloxy, dialkylamino, arylalkylamino or diarylamino; or aralkyi, n and m are integers between 0 and 15, preferentially between 0 and 3;
- R is hydrogen, alkyl, alkyl substituted with hydroxy, alkoxy, aryloxy, alkylthio, arylhio, dialkylamino, arylalkylamino or diarylamino; aralkyi, aryl, aryl substituted with alkyl, aryl, heteroaryl, halogen, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, halogen, cyano, alkoxycarbonyl or aminocarbonyl; such as benzyl
- R is hydrogen, alkyl optionally substituted with hydroxy, halogen, cyano, alkoxy, aryloxy, dialkylamino, arylalkylamino or diarylamino; or aralkyi; such as hydrogen
- 1 4 5 6 1 1 R may be covalently linked to E, R , R and/or R , in which case -R -E- or -R -
- R - represents low alkylene, preferentially methylene, ethylene or propylene, unsubstituted or substituted with alkyl, hydroxy, alkoxycarbonyl, alkoxy or dialkylamino; -
- R -R - represents ethylene or propylene, unsubstituted or substituted with alkyl, hydroxy, alkoxy or dialkylamino; and/or -R -R - represents methylene, propylene or butylene unsubstituted or substituted with alkyl, hydroxy, alkoxycarbonyl, alkoxy or dialkylamino;
- R is alkyl optionally substituted with aryl, heteroaryl, alkoxy, aryloxy, cyano, dialkylamino, arylalkylamino, diarylamino or halogen; aryl optionally substituted with alkyl, aryl, heteroaryl, halogen, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, halogen, cyano, alkoxycarbonyl or aminocarbonyl; heteroaryl optionally substituted with alkyl, aryl, heteroaryl, halogen, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, halogen, cyano, alkoxycarbonyl or aminocarbonyl; such as 4-chlorophenyl, methyl or isopropyl, and R 2 is cyano, -CO-R', -CO 2 R', -CONHR', -CONR'R", or
- Su is a substrate, such as 1% crosslinked polystyrene beads
- L is a chemical bond or a linker, such as 4-hydroxybenzylalcohol (Wang linker),
- A is a electron-withdrawing group of formula
- Y is an amino group or an aryl group, such as phenyl
- E' is a chemical bond or a group of formula
- G' may be -O-, -NH-, -NH-peptide-O- or -NH-peptide-NH-
- R is alkylene optionally substituted with hydrogen, alkyl, aryl, heteroaryl, alkoxy, aryloxy, cyano, hydroxy, dialkylamino, arylalkylamino, diarylamino or halogen, such as methylene, 1 ,2-ethylene, 1 ,4-butylene, or 1 ,3-pentylene,
- R is hydrogen, alkyl optionally substituted with hydroxy, halogen, cyano, alkoxy, aryloxy, dialkylamino, arylalkylamino or diarylamino; or aralkyi; n and m are integers between 0 and 15, preferentially 0 and 3;
- R is hydrogen, alkyl, alkyl substituted with hydroxy, alkoxy, aryloxy, alkylthio, arylthio, dialkylamino, arylalkylamino or diarylamino; aralkyi, aryl, aryl substituted with alkyl, aryl, heteroaryl, halogen, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, halogen, cyano, alkoxycarbonyl or aminocarbonyl; such as benzyl,
- R is hydrogen, alkyl optionally substituted with hydroxy, halogen, cyano, alkoxy, aryloxy, dialkylamino, arylalkylamino or diarylamino; or aralkyi, such as hydrogen,
- R - represents low alkylene, preferentially methylene, ethylene or propylene, unsubstituted or substituted with alkyl, hydroxy, alkoxycarbonyl, alkoxy or dialkylamino; -
- R -R - represents ethylene or propylene, unsubstituted or substituted with alkyl, hydroxy,
- R is alkyl optionally substituted with aryl, heteroaryl, alkoxy, aryloxy, cyano, dialkylamino, arylalkylamino, diarylamino or halogen; aryl optionally substituted with alkyl, aryl, heteroaryl, halogen, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, halogen, cyano, alkoxycarbonyl or aminocarbonyl; heteroaryl optionally substituted with alkyl, aryl, heteroaryl, halogen, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, halogen, cyano, alkoxycarbonyl or aminocarbonyl; such as 4-chlorophenyl, methyl or isopropyi; and
- R 2 is cyano, -CO-R', -CO 2 R', -CONHR', -CONR'R", or -C(OH)-R ⁇ R' being alkyl, alkyl substituted with halogen, aryl, aryl substituted with alkyl, aryl, heteroaryl, halogen, alkoxy, aryloxy, dialkylamino, alkylarylamino, diarylamino, halogen, cyano, alkoxycarbonyl or aminocarbonyl or heteroaryl; and R" being alkyl or substituted or unsubstituted aryl; such as benzoyi, 2,4-dichlorobenzoyl, 4-chloro-3-methylbenzoyl, 4-phenylbenzoyl, 2- naphthoyl or 4-(methylsulfonylamino)benzoyl; and
- High throughput screening generally incorporates automation and robotics, thus making it possible to screen thousands of compounds in one or more bioassays in a short period of time. This technique has created the need for an automated production of large numbers of different compounds for being screened.
- a robotic, fully automated system for the production and screening of highly diverse compounds as potential lead-candidates will dramatically speed up the discovery and optimization of new leads for all types of human diseases.
- Linear syntheses involve the sequential reactions of several separate reactants in order to obtain the final product.
- Linear syntheses require the isolation, purification and characterization by spectroscopic and other analytical tools of the intermediate reaction products.
- Such a linear synthesis is therefore a very time consuming process, which requires a high skill in the synthetic organic chemical art. Since this traditional way of producing compounds is too inefficient for fully exploiting the screening-potential of presently available systems for high throughput screening, synthetic methodology is required, which permits the automated synthesis of large numbers of different compounds.
- Thiophenes are important core structures for biologically active compounds. (S. Gronowitz, Adv. Heterocycl. Chem. 1963, 7, 1 ; H. D. Hartough, Chem. Heterocycl. Compd. 1952, 3, 1 ; M. Chaykovsky et al., J. Med. Chem. 1973, 6, 188; A. Michiel van Rhee et. al, J. Med. Chem. 1996, 39, 398-406).
- Thiophene derivatives have for instance also been used as analgetics (tinoridine, diethylthiambutene), anti-inflammatories (suprofen, tiaprofenic acid), antihelmintics (morantel, pyrantel, thenium chlosylate), anticholinergics (heteronium bromide, oxitefonium bromide, penthienate bromide, tiquizinium bromide, thihexinol methylbromide, thiemonium bromide), antihistaminics (chlorothen, thenalidine, methaphenilene, methapyrilene, thenyldiamine) and antiussives (tipepidine).
- analgetics tinoridine, diethylthiambutene
- anti-inflammatories suprofen, tiaprofenic acid
- antihelmintics morantel, pyrantel, thenium
- Thiophene derivatives have been used as anticholesteremics (Bryant, H. U.; Grese, T. A., Can. Pat. Appl. CA 2,117,853 (1995), Chemical Abstracts 1995, 123, 339713y) or for the treatment of disorders associated with amyloidogenic peptides (Lunn, W. H. W., PCT Int. Appl. WO 95 17,095 (1995), Chemical Abstracts 1995, 723, 339715a).
- the present invention provides a solid phase synthesis for thiophenes in which variable substituent groups are independently attached to a common central thiophene ring.
- the generally recognized advantages of solid phase synthesis are the absence of purification steps of intermediates or the final product, as well as the possibility of automation. Due to these features, a solid phase synthesis of thiophenes dramatically increases the synthesis efficiency for these therapeutically important compounds.
- Alkyl is intended to mean lower straight, cyclic, fused or branched alkyl having 1 to 15 carbon atoms, preferentially 1 to 6 carbon atoms.
- Aryl is intended to mean phenyl or phenyl substituted with alkyl or phenyl, or phenyl fused with cycloalkyl, or polycyclic aromatic systems such as naphthyl, anthracenyl, phenanthrenyl, fluorenyl, etc.
- Alkylene is intended to mean lower straight, cyclic, fused or branched alkylene having 1 to 15 carbon atoms, preferentially 1 to 6 carbon atoms.
- Heteroaryl is intended to mean any of the possible isomeric, unsubstituted or alkyl-substituted pyrrolyl, furyl, thienyi, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrazinyi, pyrimidinyl and pyridazinyl, as well as the corresponding benzo and dibenzo derivatives or other fused ring-systems thereof. Heteroaryl is also intended to mean the partially or fully hydrogenated derivatives of the heterocyclic systems enumerated above.
- Alkylthio is intended to mean -S-alkyl and arylthio is intended to mean -S-aryl.
- Alkoxycarbonyl is intended to mean -CO- O-alkyl and aminocarbonyl is intended to mean -CO-N(alkyl)2, -CO-N(alkyl)(aryl) or -CO- N(aryl)2- Acylamino is intended to mean -N(alkyl)-CO-alkyl or -N(alkyl)-CO-aryl.
- a leaving group is intended to be a group or atom capable of existing in solution as a negatively charged species, or a positively charged group or atom.
- HO2C-CH(R 6 )-N(R 1 )H or HO 2 C-peptide-N(R 1 )H is attached to or prepared on a substrate Su via a linker L by well precedented methods, in such a way, that a free primary or secondary amino group is generated on the support.
- the substrate may be any insoluble or partially insoluble material, to which compounds may be covalently attached.
- the substrates may be selected from the group consisting of polystyrene, polyethylene glycol (PEG), polyethylene glycol attached to polystyrene (e.g. TentaGel), poiyamides, polysaccharides and silicates.
- PEG polyethylene glycol
- TentaGel polyethylene glycol attached to polystyrene
- poiyamides e.g. TentaGel
- polysaccharides e.g., polysaccharides and silicates.
- different types of solvents or protecting groups may be used.
- a polystyrene resin or TentaGel covalently attached to a Rink linker
- a polystyrene resin or TentaGel covalently attached to a Rink linker
- a Rink linker H. Rink, Tetrahedron Lett. 1987, 28, 3787
- may be acylated with a derivative of a side-chain and nitrogen-protected e.g.
- the nitrogen protecting group may be removed by well established methods, such as treatment with piperidine in DMF in the case of an FMoc-protecting group, to give a substrate-bound amino acid of the general formula [polystyrene or fi 1
- a base preferentially a tertiary amine
- the resulting intermediate is then reacted with a compound of the general formula A-CH 2 - CN, A being an electron-withdrawing group, in the presence of a base, preferentially 1 ,8- diazabicyclo[5.4.0]undec-7-ene (DBU).
- DBU diazabicyclo[5.4.0]undec-7-ene
- R 3 being straight or branched alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, including n-butyl, sec-butyl, iso- butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, etc., and their variants, straight or branched alkylene chains such as methylene, 1 ,2-ethylene, 1 ,1-ethylene, propylene, etc.
- substituted or unsubstituted aryl groups such as phenyl, naphthyl, biphenylyl or monovalent radicals of substituted or unsubstituted heterocycles and heteroaromatics such as pyridyl, thienyl, pyrrolyl, furyl, piperidinyl, pyrrolidinyl, etc.
- R may be substituted or unsubstituted aryl groups or substituted or unsubstituted heterocycles or heteroaromatics. All these groups may also be substituted with functional groups such as F, Cl, Br, I, CONR2, CO2R, CN, NO2 . SR, SOR, SO2R, SO2NR2, OR or NR2, R being low alkyl or aryl.
- the resulting substrate-bound thioamide 2 may now be alkylated at sulfur with a compound of the general formula R 2 -CH 2 -X, X being -OH or a leaving group for nucleophilic displacement, such as chloride or bromide and R 2 being an electron- withdrawing group as e.g.
- aryl groups such as phenyl, naphthyl, biphenylyl or monovalent radicals of substituted or unsubstituted heterocycles and heteroaromatics such as pyridyl, thienyl, pyrrolyl, furyl, piperidinyl,
- R may be substituted or unsubstituted aryl groups or substituted or unsubstituted heterocycles or heteroaromatics. All these groups may also be substituted with functional groups such as F, Cl, Br, I, CONR2, CO2R, CN, NO2, SR, SOR, SO2R, SO2NR2, OR or NR2, R being low alkyl or aryl.
- This alkylation is carried out in an appropriate solvent such as DMF, DCM, acetonitrile or THF, either under neutral or acidic conditions.
- the leaving group X may be, for instance
- the resulting, S-alkylated intermediate may be treated with a base, such as DBU, guanidines, potassium hexamethyldisilazide or alcoholates, in an appropriate solvent such as DMF, THF, toluene, alcohols or acetonitrile, thereby inducing a Thorpe-Ziegler-cyclization to the substrate-bound thiophene II.
- a base such as DBU, guanidines, potassium hexamethyldisilazide or alcoholates
- an appropriate solvent such as DMF, THF, toluene, alcohols or acetonitrile
- Cleavage of the linker of the substrate-bound thiophene II may release the 3- aminothiophene derivative I into solution. Cleavage conditions will depend upon the type of substrate and linker chosen. E. g., in the case of a polystyrene resin with a Wang linker or a Rink linker, treatment of the support-bound thiophene II with neat TFA or TFA/DCM mixtures may lead to a cleavage of the linker.
- further chemical transformations may be carried out with the substrate- bound thiophene II.
- These comprise the acylation at the 3-amino group with e.g. carboxylic acid derivatives, sulfonic acid derivatives, isocyanates or isothiocyanates.
- R -COR', R' being hydrogen or substituted or unsubstituted alkyl or aryl
- the reduction of the keto group in the resin bound thiophene II may yield a primary or secondary alcohol, which may be cleaved from the support or first acylated with carboxylic acid derivatives, sulfonic acid derivatives, isocyanates or isothiocyanates either at the hydroxy group or at the amino group, the site of acylation depending on the precise 2 reaction conditions, and then cleaved from the support.
- R -COR', R' being hydrogen or substituted or unsubstituted alkyl or aryl
- keto- or formyl-group of the substrate-bound thiophene II may be chemically transformed in numerous ways, obvious to those skilled in the art. It may be converted into a hydrazone or an oxime, it may be reductively aminated or reacted with organometallic reagents or condensed with CH-acidic compounds such as nitroaikanes, 1 ,3-dicarbonyl compounds, malononitrile, disulfonyl methanes, etc. Each of these reactions may be performed by conventional means, readily apparent to those skilled in the art.
- the thiophenes of formula I wherein Y is an aryl, such as phenyl may be prepared by a method analogous to that outlined above and shown in scheme 1 , wherein the acceptor- substituted acetonitrile A-CH 2 -CN is replaced by either an acyiacetonitrile of the general formula Y-CO-CH 2 -CN or a ketone of the general formula Y-CO-CH 2 -Z, Z being an electron-withdrawing group such as -N0 2 , -O 2 R 4 , -C0 2 R 4 , -CONR 4 R 5 or -COR 4 .
- thiophenes of formula I and II appear as 3- aminothiophenes it is not ment as a limitation and should be construed as also including such thiophenes of formula I and II wherein Y is aryl, preferably phenyl.
- arrays of thiophene derivatives 11 or I may be constructed with the help of a device for parallel solid phase synthesis.
- a device for parallel solid phase synthesis This may be either the pin method developed by Geysen et al. (J Immunol. Meth. 1987, 702, 259-274) or a device with several reactors for solid phase synthesis (containers with a permeable wall), which permits the automated addition of reagents and solvents, as well as the removal of the solvents from the reactors by simultaneous or individual application of a pressure difference between the inside and the outside of the permeable wall of the reactors.
- Such an array may be prepared on a multiple organic synthesizer (e.g. "ACT 496” of “Advanced ChemTech”) by individually reacting under the conditions specified below different amines attached to a substrate and located in individual containers, with carbondisulfide and p-toluenesulfonylchloride or thiophosgene or a thiophosgene equivalent in the presence of a base, followed by treatment with different acceptor- substituted acetonitriles of the general formula A-CH 2 -CN, also in the presence of a base.
- ACT 496 of "Advanced ChemTech”
- the resulting substrate-bound thioamides 2 may now be alkylated at sulfur with different alkylating agents of the general formula R 2 -CH 2 -X to give, after treatment with a base and optional cleavage from the support, an array of different thiophene derivatives I or II.
- the present invention also permits the synthesis of arrays of mixtures of thiophene derivatives. This can be achieved either by the "split and mix” method (Sepetov, N.F., Krchnak, V., Stankova, M., Wade, S., Lam, K.S., and Lebl Proc. Natl. Acad. Sci. USA 1995, 92, 5426-5430) or by using mixtures of the corresponding reagents.
- FCA fully combinatorial arrays
- NFCA not-fully combinatorial arrays
- FCA we refer to arrays of substituted thiophenes, in which all the possible combinations of a set of selected building blocks are realized.
- the selection of building blocks may be done with regard to the expected properties of the members of the array.
- NFCA By NFCA we refer to arrays of substituted thiophenes, in which only a selection of the possible combinations of a set of selected building blocks is realized.
- a NFCA of N thiophenes may be prepared by first selecting n diamines, m acceptor- substituted acetonitriles and p haloketones so that n x m x p > N.
- N thiophenes from all the n x m x p theoretically possible thiophenes is done by grouping all the n x m x p possible thiophenes into N groups of thiophenes with similar expected properties and selecting from each of these groups one thiophene, which is then synthesized.
- the selection of building blocks and of thiophenes may be done with regard to the expected properties of the members of the array.
- the exact positions of the substrate does, by itself, not give any structural information about the compound prepared on this particular batch of substrate. For this reason, the spatial arrangement of the substrate is irrelevant. Structural information will be accessible from the records of the sequences of reagents added to each batch of substrate. In every step of the preparation of a FCA or a NFCA, the exact location of one substrate-container within the array of containers and the structure of the different reagents added to this container is recorded, so that the precise structure of the thiophene resulting from one given container can always be deduced.
- the resulting arrays of 2-aminothiophenes may then be screened by comparing the individual thiophenes in terms of their ability to bind to a particular receptor or to induce a particular biological process or to catalyze a biological or chemical reaction.
- This can be achieved basically in two different ways.
- One possibility may be the screening of the substrate-bound thiophenes II, e.g. against a soluble receptor. This could for instance be a radioactively labelled peptide or enzyme, which would easily permit to determine the binding-strength of a given substrate-bound thiophene II to this peptide by washing away the excess of radioiigand used and determining the remaining radioactivity of each substrate-bound thiophene ll-peptide complex.
- catalytic activity of the different substrate-bound thiophenes II for a given biological process or a chemical reaction may be measured by comparing the speed at which this biological process or a chemical reaction takes place in the presence and in the absence of a given substrate-bound thiophene II.
- the second option for screening may consist in screening the thiophenes I, after having cleaved the linker of the substrate-bound thiophenes II and using appropriately charged and indexed Microtiter plates of similar multiwell arrangements, in solution against an optionally substrate-bound receptor or enzyme.
- the screening of soluble small molecules is conventional and well known.
- radioassays are being used, in which the competitive binding of the radioiabelled, natural ligand of a given receptor and the compound to be tested for binding to this receptor is investigated.
- cholecystokinine receptors which are widely distributed throughout the central and peripheral nervous system and mediate numerous physiological responses.
- Crude membrane homogenates may be prepared according to the procedure described by Chang et al. (Proc. Natl. Acad. Sci. 1986, 4923- 4926) and radiolabelled cholecystokinine can be purchased from New England Nuclear, Massachusetts, U.S.A.
- Other examples will be readily apparent to those skilled in the arts of physiology, biology and biotechnology. These could for instance be the somatostatine receptors, the glucagon receptors, the insulin receptor, the opiate receptors, the dopamine receptors, the acetylcholine receptors, the histamine receptors, etc.
- functional or other assays may be used, in which for example the biological response of a cell or a genetically modified or unmodified organism is measured as a function of the amount of test-substance added to this organism.
- the catalytic activity of the different thiophenes I for a given biological process or a chemical reaction may be measured by comparing the speed at which this biological process or a chemical reaction takes place in the presence and in the absence of a given thiophene I.
- Zaragoza, F Solid-phase Synthesis of substituted 3-Aminothiophenes and 2- Methylene-2,3-dihydrothiazoles, Tetrahedron Lett. 1996, 37, 6213-6216.
- ChemTech the four diamines 1 ,2-diaminoethane, 1 ,4-diaminobutane, 1 ,3-diamino-2,2- dimethylpropane and 1 ,3-diaminopentane, previously attached to a Wang resin via a carbamate-group, were equally distributed [150 mg (approx. 0.14 mmol) of each resin- bound diamine into each of twenty reactors].
- the array of reactors was shaken for 15 h, the resins filtered and washed with 1 ,2-dichloroethane and then reacted with four different acceptor-substituted acetonitriles [malonodinitrile, (4-chiorophenyl)sulfonylacetonitrile, methylsulfonyl-acetonitrile, isopropylsulfonylacetonitrile] in the presence of DBU (as described above) in such a way, that all possible combinations of diamines and acceptor-substituted acetonitriles was realized.
- acceptor-substituted acetonitriles malonodinitrile, (4-chiorophenyl)sulfonylacetonitrile, methylsulfonyl-acetonitrile, isopropylsulfonylacetonitrile
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU56518/98A AU5651898A (en) | 1997-02-20 | 1998-01-29 | Solid phase and combinatorial synthesis of substituted thiophenes and of arrays of substituted thiophenes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK17797 | 1997-02-20 | ||
DK0177/97 | 1997-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998037078A1 true WO1998037078A1 (fr) | 1998-08-27 |
Family
ID=8090643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1998/000035 WO1998037078A1 (fr) | 1997-02-20 | 1998-01-29 | CHIMIE EN PHASE SOLIDE ET SYNTHESE COMBINATOIRE DE THIOPHENES SUBSTITUES ET DE SERIES DE CES thiofènes SUBSTITUES |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5651898A (fr) |
WO (1) | WO1998037078A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1242080A1 (fr) * | 1999-09-27 | 2002-09-25 | Georgetown University | Inhibiteurs du transporteur de dopamine et leur utilisation |
WO2006078287A3 (fr) * | 2004-05-06 | 2007-03-29 | Plexxikon Inc | Inhibiteurs de pde4b |
US7932213B2 (en) | 1999-05-11 | 2011-04-26 | President And Fellows Of Harvard College | Small molecule printing |
-
1998
- 1998-01-29 AU AU56518/98A patent/AU5651898A/en not_active Abandoned
- 1998-01-29 WO PCT/DK1998/000035 patent/WO1998037078A1/fr active Application Filing
Non-Patent Citations (5)
Title |
---|
EDUARD R. FELDER, "The Challenge of Preparing and Testing Combinatorial Compound Libraries in the Fast Lane, at the Front End of Drug Development", CHIMIA, Volume 48, 1994, pages 531-541. * |
ERIC M. GORDON, "Libraries of Non-Polymeric Organic Molecules", CURRENT OPINION IN BIOTECHNOLOGY, Volume 6, 1995, pages 624-631. * |
FLORENCIO ZARAGOZA, "Solid-Phase Synthesis of Substituted 3-Aminothiophenes and 2-Methylene-2,3-Dihydrothiazoles", TETRAHEDRON LETTERS, Volume 37, No. 34, 1996, pages 6213-6216. * |
HENRIK STEPHENSEN et al., "Resin-Bound Isothiocyanates and Their Synthetic Equivalents as Intermediates for the Solid-Phase Synthesis of Substituted Thiophenes", J. ORG. CHEM., Volume 62, Sept. 1997, pages 6096-6097. * |
JOERG S. FRUECHTEL et al., "Organic Chemistry on Solid Supports", ANGEW. CHEM. INT. ED., Volume 35, 1996, pages 17-42. * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7932213B2 (en) | 1999-05-11 | 2011-04-26 | President And Fellows Of Harvard College | Small molecule printing |
EP1242080A1 (fr) * | 1999-09-27 | 2002-09-25 | Georgetown University | Inhibiteurs du transporteur de dopamine et leur utilisation |
EP1242080A4 (fr) * | 1999-09-27 | 2003-01-22 | Univ Georgetown | Inhibiteurs du transporteur de dopamine et leur utilisation |
WO2006078287A3 (fr) * | 2004-05-06 | 2007-03-29 | Plexxikon Inc | Inhibiteurs de pde4b |
JP2008503446A (ja) * | 2004-05-06 | 2008-02-07 | プレキシコン,インコーポレーテッド | Pde4b阻害剤及びその使用 |
US7585859B2 (en) * | 2004-05-06 | 2009-09-08 | Plexxikon, Inc. | PDE4B inhibitors and uses therefor |
US8470821B2 (en) | 2004-05-06 | 2013-06-25 | Plexxikon Inc. | PDE4B inhibitors and uses therefor |
Also Published As
Publication number | Publication date |
---|---|
AU5651898A (en) | 1998-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5847150A (en) | Solid phase and combinatorial synthesis of substituted 2-methylene-2, 3-dihydrothiazoles and of arrays of substituted 2-methylene-2, 3-dihydrothiazoles | |
CA2187969C (fr) | Modele pour la synthese en solution de composes de bibliotheques combinatoires | |
US5545568A (en) | Solid phase and combinatorial synthesis of compounds on a solid support | |
US6306959B1 (en) | Rapid purification by polymer supported quench | |
AU704183B2 (en) | Systematic modular production of aminimide- and oxazolone-based molecules having selected properties | |
WO1995024186A1 (fr) | Derives de sulfonamide et leurs utilisations | |
US6251689B1 (en) | Methods for the solid phase synthesis of combinatorial libraries of benzimidazoles benzoxazoles benzothiazoles and derivatives thereof | |
US6136984A (en) | Solid phase and combinatorial synthesis of substituted thiophenes and of arrays of substituted thiophenes | |
EP0998451B1 (fr) | 3,3-diamino-2-propenenitriles, preparation et utilisation de ces derniers | |
WO1998037078A1 (fr) | CHIMIE EN PHASE SOLIDE ET SYNTHESE COMBINATOIRE DE THIOPHENES SUBSTITUES ET DE SERIES DE CES thiofènes SUBSTITUES | |
Fujimori et al. | Preparation of a Kröhnke pyridine combinatorial library suitable for solution-phase biological screening | |
Wade et al. | Application of base cleavable safety catch linkers to solid phase library production | |
AU678168B2 (en) | Oxazolone derived materials | |
Richter et al. | Curtius degradation in solid-phase synthesis | |
WO1997040025A1 (fr) | Phase solide et synthese combinatoire de 1,2,3-triazoles substitues, et reseaux de 1,2,3-triazoles substitues | |
US5955548A (en) | Substituted 3, 3-diamino-2-propenenitriles, their preparation and use | |
WO1994000509A9 (fr) | Matieres derivees d'oxazolone | |
US6245937B1 (en) | Liquid phase parallel synthesis of chemical libraries | |
JPH10500685A (ja) | 少なくとも2つの構造多様性要素をもつアミンイミドおよびオキサゾロンをベースとした分子の系統的モジュール製造 | |
Fukumoto et al. | Development of a solid-supported biotinylation reagent for efficient biotin labeling of SH groups on small molecules | |
JPH09511225A (ja) | オキサゾロン誘導分子のモジュール設計および合成 | |
Feider et al. | 3.4 Combinatorial Synthesis of Heterocycles | |
US7034110B2 (en) | Method of identifying chemical compounds having selected properties for a particular application | |
US20020146684A1 (en) | One dimensional unichemo protection (UCP) in organic synthesis | |
KR100465353B1 (ko) | 하이드라진 유도체 및 그의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998536170 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |